Inactive Instrument

Analyst Reco. BICYCL Nasdaq

Equities

US0887861088

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

HC Wainwright Adjusts Bicycle Therapeutics Price Target to $55 From $57, Maintains Buy Rating	Feb. 21	MT
JMP Securities Cuts Bicycle Therapeutics Price Target to $32 From $44, Maintains Market Outperform Rating	Dec. 20	MT
Morgan Stanley Cuts Price Target on Bicycle Therapeutics to $40 From $42, Maintains Equal-Weight Rating	Nov. 03	MT
B. Riley Upgrades Bicycle Therapeutics to Buy From Neutral After Announced Alignment With US FDA on Phase 2/3 Registrational Trial for BT8009 for Metastatic Bladder Cancer; PT is $33	23-09-12	MT
Oppenheimer Adjusts Bicycle Therapeutics Price Target to $48 From $55, Maintains Outperform Rating	23-08-04	MT
JMP Securities Adjusts Price Target on Bicycle Therapeutics to $44 From $46, Maintains Outperform Rating	23-08-04	MT
Needham Adjusts Price Target on Bicycle Therapeutics to $46 From $48, Maintains Buy Rating	23-08-04	MT
Needham Adjusts Price Target on Bicycle Therapeutics to $64 From $67, Maintains Buy Rating	23-05-05	MT
Needham Adjusts Price Target on Bicycle Therapeutics to $67 From $72, Keeps Buy Rating	23-03-01	MT
EF Hutton Initiates Bicycle Therapeutics at Buy, $55 Price Target	23-01-05	MT
JMP Securities Adjusts Price Target on Bicycle Therapeutics to $46 From $70, Maintains Market Outperform Rating	22-11-09	MT
Morgan Stanley Lowers Price Target on Bicycle Therapeutics to $45 From $60, Keeps Equalweight Rating	22-09-12	MT
Bicycle Therapeutics Shares Rise After Cowen Initiates Coverage	22-08-31	MT
Cowen Initiates Coverage on Bicycle Therapeutics With Outperform Rating	22-08-31	MT
SVB Securities Lifts Price Target on Bicycle Therapeutics to $50 From $48, Keeps Outperform Rating	22-08-22	MT
HC Wainwright Lowers Bicycle Therapeutics Price Target to $57 From $65, Maintains Buy Rating	22-08-05	MT
Barclays Initiates Bicycle Therapeutics at Overweight With $30 Price Target	22-07-28	MT
Canaccord Genuity Assumes Bicycle Therapeutics at Buy with $60 Price Target	22-07-06	MT
Piper Sandler Lowers Bicycle Therapeutics' Price Target to $37 From $76, Maintains Overweight Rating	22-05-23	MT
B. Riley Downgrades Bicycle Therapeutics to Neutral from Buy, Finds Significantly More Risk in Bicycle Toxin Conjugate Platform; Lowers Price Target to $33 from $62	22-04-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. BICYCL Nasdaq

Equities

US0887861088

Analyst Reco.

Filters